• 1
    Coiffier B, Lepage E, Briere J, et al. CHOP plus rituximab with CHOP chemotherapy in elderly patients with diffuse large B-Cell lymphoma. A Groupe d'Etude des Lymphomes de l'Adulte study. N Engl J Med. 2002; 346: 235-242.
  • 2
    Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005; 105: 1417-1423.
  • 3
    Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 1999; 17: 268-276.
  • 4
    Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003; 101: 2377-2380.
  • 5
    Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2005; 23: 667-675.
  • 6
    O'Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol. 2005; 23: 676-684.
  • 7
    Benichou J, Bellissant E, Chastang C. Analysis of phase II clinical trials in haematology and oncology: comparison of the triangular test to the usual methods. Stat Med. 1991; 10: 989-990.
  • 8
    Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol. 1999; 17: 1244-1253.
  • 9
    Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006; 24: 4867-4874.
  • 10
    Belch A, Kouroukis CT, Crump M, et al. A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group Trial IND. 150. Ann Oncol. 2007; 18: 116-121.
  • 11
    Orlowski RZ, Voorhees PM, Garcia RA, et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood. 2005; 105: 3058-3065.
  • 12
    Leonard JP, Furman RR, Cheung YK, et al. CHOP-R + bortezomib as initial therapy for diffuse large B-cell lymphoma (DLBCL) [abstract]. J Clin Oncol. 2007; 25: 18S. Abstract 8031.
  • 13
    Kahl B, Chang J, Eickhoff J, et al. VcR-CVAD produces a high complete response rate in untreated mantle cell lymphoma: a phase II study from the Wisconsin Oncology Network [abstract]. Blood. 2008; 112: 11S. Abstract 265.